Patents Assigned to Pharma Mar, S.A.
  • Antibody drug conjugates comprising ecteinascidin derivatives
    Patent number: 12653900
    Abstract: Drug conjugates having formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, (I) wherein D is covalently attached via a hydroxy or amine group to (X)b if any, or (AA)w if any, or to (T)g if any, or (L); that are useful in the treatment of cancer.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: June 16, 2026
    Assignee: PHARMA MAR, S.A.
    Inventors: Maria del Carmen Cuevas Marchante, Andrés M. Francesch Solloso, Alfonso Latorre Lozano, Valentin Martinez Barrasa
  • PLD for use in combination in the treatment of coronavirus
    Patent number: 12648986
    Abstract: The use of PLD with one or more further CoV antiviral agent(s) in the treatment of coronavirus (CoV) infection.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: June 9, 2026
    Assignee: PHARMA MAR, S.A.
    Inventors: Nuria Izquierdo-Useros, Júlia Vergara-Alert, Pablo Avilés Marín, Alejandro Losada González, José María Fernández Sousa-Faro, Salvador Fudio Muñoz
  • Compounds for use in viral infections
    Patent number: 12630589
    Abstract: The present invention relates to the use of compounds in the treatment of a viral infection, wherein the virus is selected from the Orthomyxoviridae family or wherein the virus is West Nile virus.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: May 19, 2026
    Assignee: PHARMA MAR, S.A.
    Inventors: Pablo Avilés Marín, Alejandro Losada González, José María Fernández Sousa-Faro, Salvador Fudio Muñoz
  • Method of treating SCLC and managing thrombocytopenia
    Patent number: 12440490
    Abstract: Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
    Type: Grant
    Filed: August 10, 2023
    Date of Patent: October 14, 2025
    Assignee: PHARMA MAR, S.A.
    Inventors: Carmen Kahatt, José María Fernandez, Salvador Fudio, Arturo Soto, Pilar Lardelli, Cristian Fernandez
  • Method of treating SCLC and managing neutropenia
    Patent number: 12433890
    Abstract: Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
    Type: Grant
    Filed: August 10, 2023
    Date of Patent: October 7, 2025
    Assignee: PHARMA MAR, S.A.
    Inventors: Carmen Kahatt, José María Fernandez, Salvador Fudio, Arturo Soto, Pilar Lardelli, Cristian Fernandez
  • Antitumoral compounds
    Patent number: 12384800
    Abstract: A compound of general formula I and pharmaceutical compositions, kits, methods of making, and methods for treating cancer using the same.
    Type: Grant
    Filed: June 22, 2023
    Date of Patent: August 12, 2025
    Assignee: PHARMA MAR, S.A.
    Inventors: Maria del Carmen Cuevas Marchante, Andres Francesch Solloso, Valentin Martinez Barrasa
  • Method of treating SCLC and managing hepatotoxicity
    Patent number: 12324806
    Abstract: Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
    Type: Grant
    Filed: August 10, 2023
    Date of Patent: June 10, 2025
    Assignee: PHARMA MAR, S.A.
    Inventors: Carmen Kahatt, José María Fernandez, Salvador Fudio, Arturo Soto, Pilar Lardelli, Cristian Fernandez
  • Anticancer compounds
    Patent number: 12215100
    Abstract: Anticancer compounds of formula (I) and derivatives thereof are provided.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: February 4, 2025
    Assignee: PHARMA MAR, S.A.
    Inventors: María Jesús Martín López, Raquel Rodríguez Acebes, Patricia Gema Cruz López, Andrés M. Francesch Solloso, Maria del Carmen Cuevas Marchante
  • Antitumoral compounds
    Patent number: 11713325
    Abstract: A compound of general formula I and pharmaceutical compositions, kits, methods of making, and methods for treating cancer using the same.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: August 1, 2023
    Assignee: Pharma Mar, S.A.
    Inventors: Maria del Carmen Cuevas Marchante, Andres Francesch Solloso, Valentin Martinez Barrasa
  • Combination therapy with an antitumor alkaloid
    Patent number: 11590129
    Abstract: The present invention relates to the combination of PM01183 with several anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and/or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734 and PM00104, and the use of these combinations in the treatment of cancer.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: February 28, 2023
    Assignee: PHARMA MAR, S.A.
    Inventors: Victoria Moneo Ocaña, Gema Santamaría Núñez, Luis Francisco García Fernández, Carlos María Galmarini, María José Guillén Navarro, Pablo Manuel Avilés Marín
  • Antitumoral compounds
    Patent number: 11339180
    Abstract: A compound of general formula I and pharmaceutical compositions, kits, methods of making, and methods for treating cancer using the same.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: May 24, 2022
    Assignee: PHARMA MAR, S.A.
    Inventors: María del Carmen Cuevas Marchante, Andrés Francesch Solloso, Valentín Martínez Barrasa
  • Antitumoral compounds
    Patent number: 11332480
    Abstract: A compound of general formula I, wherein X, R1-R4 take various meanings, for use in the treatment of cancer.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 17, 2022
    Assignee: PHARMA MAR, S.A.
    Inventors: María del Carmen Cuevas Marchante, Andrés Francesch Solloso, Valentín Martínez Barrasa
  • Antibody drug conjugates
    Patent number: 11224663
    Abstract: Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and (III) R1, R2 and R3 is H, ORa, OCORa, OCO—ORa, alkyl, alkenyl, alkynyl, etc.; R3? is, CORa, COORa, CONRaRb, etc; each of R4 to R10 and R12 is alkyl, alkenyl or alkynyl; R11 is H, CORa, COORa, alkyl, alkenyl or alkynyl, or R11 and R12+N+C atoms to which they are attached may form a heterocyclic group; each of R13 and R14 is H, CORa, COORa, alkyl, alkenyl or alkynyl; each Ra and Rb is H, alkyl, alkenyl, alkynyl, etc.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: January 18, 2022
    Assignee: PHARMA MAR, S.A.
    Inventors: Cármen Cuevas Marchante, Juan Manuel Domínguez Correa, Andrés Francesch Solloso, María Garranzo García-Ibarrola, María José Munoz Alonso, Francisco Sánchez Madrid, Juan Manuel Zapata Hernández, Alicia García Arroyo, Maria Ángeles Ursa Pecharromán
  • Antitumoral compounds
    Patent number: 10538535
    Abstract: A compound of general formula I, wherein X, R1-R4 take various meanings, for use in the treatment of cancer.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: January 21, 2020
    Assignee: PHARMA MAR, S.A.
    Inventors: María del Carmen Cuevas Marchante, Andrés Francesch Solloso, Valentín Martínez Barrasa
  • Antitumoral compounds
    Patent number: 10442820
    Abstract: A compound of general formula I, wherein X, R1-R4 take various meanings, for use in the treatment of cancer.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 15, 2019
    Assignee: PHARMA MAR, S.A.
    Inventors: María del Carmen Cuevas Marchante, Andrés Francesch Solloso, Valentín Martínez Barrasa
  • Antitumoral compounds
    Patent number: 9827257
    Abstract: A compound of general formula (I) wherein A, Y, R1, R2, R3, R4, R5, and R6 take various meaning or use in the treatment of cancer.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: November 28, 2017
    Assignee: PHARMA MAR, S.A.
    Inventors: Alberto Rodriquez Vicente, Maria Garranzo Garcia-Ibarrola, Carmen Murcia Perez, Francisco Sanchez Sancho, Maria del Carmen Cuevas Marchante, Cristina Mateo Urbano, Isabel Digon Juarez
  • Antitumoral compounds
    Patent number: 9750759
    Abstract: A compound of general formula (I) wherein A, Y, R1, R2, R3, R4, R5, and R6 take various meaning or use in the treatment of cancer.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: September 5, 2017
    Assignee: Pharma Mar, S.A.
    Inventors: Alberto Rodriquez Vicente, Maria Garranzo Garcia-Ibarrola, Carmen Murcia Perez, Francisco Sanchez Sancho, Maria del Carmen Cuevas Marchante, Cristina Mateo Urbano, Isabel Digon Juarez
  • Synthetic process for the manufacture of ecteinascidin compounds
    Patent number: 9428524
    Abstract: This invention relates to compounds of formula II: wherein R1, R2, ProtSH, and ProtNH are as defined, to processes for the synthesis of ecteinascidins of formula I from compounds of formula II, and to processes for the synthesis of compounds of formula II.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: August 30, 2016
    Assignee: PHARMA MAR, S.A.
    Inventors: Ma Jesús Martin López, Andrés Francesch Solloso, Maria del Carmen Cuevas Marchante
  • Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin-related compounds for treating proliferative diseases
    Patent number: 9192568
    Abstract: Jorumycin, renieramycin, safracin and saframycin related compounds formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: November 24, 2015
    Assignee: Pharma Mar, S.A.
    Inventors: Pilar Calvo Salve, Maria Tobio Barreira
  • Antitumoral compounds
    Patent number: 9187445
    Abstract: A compound of general formula (I) wherein A, Y, W, R1, R2, R3, R4, R5, and R6 take various meanings for use in the treatment of cancer.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: November 17, 2015
    Assignee: PHARMA MAR, S.A.
    Inventors: Alberto Rodríguez Vicente, María Garranzo García-Ibarrola, Carmen Murcia Pérez, Francisco Sánchez Sancho, María del Carmen Cuevas Marchante, Cristina Mateo Urbano, Isabel Digón Juárez